Key result
Azithromycin exposure was associated with an increased risk of QT prolongation (OR 1.40; 95% CI 1.23-1.59), particularly in elderly patients aged 60-79 years.
Why the study?
Does azithromycin exposure increase the risk of QT prolongation compared to amoxicillin in a real-world clinical setting?
Case-Control (n=402,607)
No
Does azithromycin exposure increase the risk of QT prolongation compared to amoxicillin in a real-world clinical setting?
Odds Ratio: 1.4 (95% CI 1.23–1.59)
Azithromycin exposure is associated with a significantly increased risk of QT prolongation, particularly in elderly patients aged 60-79 years, compared to amoxicillin.
No takes yet. Share an insight, caveat, or question.
Real-world azithromycin use may increase QT risk; leaves open causal cardiovascular mortality link pending higher-level evidence.
Choi et al. (2018) reported a case-control. Azithromycin vs. Amoxicillin was evaluated on QT prolongation (QTc>450 ms in male and >460 ms in female) (OR 1.40, 95% CI 1.23-1.59). Azithromycin exposure was associated with an increased risk of QT prolongation (OR 1.40; 95% CI 1.23-1.59), particularly in elderly patients aged 60-79 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: